Gottlieb Uses ASCO Platform To Unveil Two Pilot Programs To Speed Drug Review

US FDA commissioner outlines plans to allow partial submissions as soon as database locks and to create joint sponsor-agency review documents.

US FDA Commissioner Scott Gottlieb used the opening session of the American Society of Oncology annual meeting in Chicago on June 2 as an opportunity to deliver a message that the agency is laser-focused on improving the drug review process to speed new innovations to market.

"There are critics who think that we should hold drugs back from the market, and demand more pre-market studies emphasizing...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet